Previous 10 | Next 10 |
2023-03-06 17:35:39 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q4 earnings results on Tuesday, March 7th, after market close. The consensus EPS Estimate is -$0.75 (+2.6% Y/Y) and the consensus Revenue Estimate is $9.15M (+502.0% Y/Y). Over the...
2023-03-06 17:35:33 ET Major earnings expected after the bell on Tuesday include: CrowdStrike Holdings ( CRWD ) Stitch Fix ( SFIX ) Cherry Hill Mortgage Investment Corporation ( CHMI ) Yext ( YEXT ) W&T Offshore ( WTI ) For further details...
Summary This is the first 2023 update on the long-term value portfolios consistently beating the S&P 500 since inception with S&P 500 +3.40%, DJIA -2.0% YTD. For 2023 the Piotroski-Graham value portfolio is up 15.0%, Negative Forensic Portfolio is up 11.5%, and Positive Fo...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will h...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee. “Ms. Silverstein brings ...
RBC Capital Markets has initiated Marinus Pharmaceuticals ( NASDAQ: MRNS ) with an outperform rating saying that the launch of Ztalmy (ganaxolone) has been going well and will do even better with additional indications. The firm has a price target of $23 (341% upside based on Thursday...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY ® net product revenue for the fourth quarter and year ended Decembe...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 Ame...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Cha...
Collaboration leverages Tenacia’s CNS, R&D, and local market expertise to support expansion of ganaxolone’s development programs and potentially provide additional access to patients globally Marinus to receive an upfront fee of $10 million and eligible t...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus P...